TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An announcement from Shanghai Henlius Biotech, Inc. Class H ( (HK:2696) ) is now available.
Shanghai Henlius Biotech, Inc. announced that its New Drug Application for HLX14, a biosimilar of denosumab, has been accepted by the National Medical Products Administration in China. This development marks a significant step for the company as HLX14 has already been approved in the US, EU, and UK, and its acceptance in China could enhance the company’s market presence in the osteoporosis treatment sector, given the global sales of denosumab reaching approximately $7.463 billion in 2024.
The most recent analyst rating on (HK:2696) stock is a Hold with a HK$74.00 price target. To see the full list of analyst forecasts on Shanghai Henlius Biotech, Inc. Class H stock, see the HK:2696 Stock Forecast page.
More about Shanghai Henlius Biotech, Inc. Class H
Shanghai Henlius Biotech, Inc. is a biotechnology company based in China, focusing on the development and commercialization of biosimilar and innovative biologic drugs. The company specializes in creating treatments for various medical conditions, with a particular emphasis on oncology and autoimmune diseases.
Average Trading Volume: 1,465,995
Technical Sentiment Signal: Buy
Current Market Cap: HK$37.77B
For a thorough assessment of 2696 stock, go to TipRanks’ Stock Analysis page.